A patient with asthma who discontinued mepolizumab after nearly 5 years of use was admitted to the hospital, according to the results of a case study published in the European Annals of Allergy and Clinical Immunology.
A never-smoker 64-year-old Caucasian man with severe uncontrolled asthma was enrolled in the MENSA clinical trial and randomly assigned to the treatment group receiving mepolizumab. After the first month of therapy, a clinical improvement was observed, with an improvement in forced expiratory volume in 1 second.
After the conclusion of the trial, the patient continued, with subjective and clinical benefit, without exacerbations or systemic steroids needed. After 4 years and 11 months of therapy, with full control of asthma symptoms, no exacerbations, and normal lung function, mepolizumab was discontinued.